Form 4: Adaptive Biotechnologies Executive Stock Sale

President and COO Julie Rubinstein exercised options and sold shares of Adaptive Biotechnologies under a 10b5-1 plan.

Summary

• Julie Rubinstein, President and COO of Adaptive Biotechnologies, exercised options for 14,707 shares at a price of $8.46.
• Following the exercise, 19,037 shares were sold at a weighted average price of $14.23.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2025.
• The reporting person's direct beneficial ownership in common stock stands at 377,802 shares post-transaction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-established 10b5-1 trading plan, which is a standard mechanism for executive financial planning.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sale was not based on sudden non-public information.

Negatives

• The transaction represents a reduction in the executive's direct equity stake in the company.

Risks

• Executive stock sales can sometimes be perceived negatively by the market as a signal of management's view on current valuation.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is a standard corporate governance practice and typically does not reflect a change in the company's fundamental outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to manage personal liquidity while avoiding potential insider trading concerns.

Stakeholder Impact

• Shareholders should note the reduction in insider ownership, though the pre-planned nature of the sale mitigates concerns regarding management sentiment.

Next Steps

• No future actions or milestones were mentioned in this filing.

Key Dates

Keywords

Adaptive Biotechnologies, ADPT, Insider Trading, Form 4, Julie Rubinstein, Stock Option Exercise